Dr. James MacDonald
Provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, Hurel Corporation, has announced the appointment of Dr. James MacDonald to the Board of Directors.
MacDonald is the former Executive Vice President of Preclinical Development of the Schering-Plough Research Institute, which was the pharmaceutical development arm of Schering Corporation prior to its acquisition by Merck & Co. in 2009.
“Hµrel is privileged to benefit from Jim's extraordinary wisdom and experience, both as a scientist and as a drug development executive. His guidance will be invaluable,” said Robert Freedman, Hµrel's Chairman and CEO.